Related references
Note: Only part of the references are listed.Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study
S. Modi et al.
CANCER RESEARCH (2019)
47OPhase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer
M Pegram et al.
ANNALS OF ONCOLOGY (2018)
NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) -> weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+or 2+with negative FISH (HER2-Low IBC)
Louis Fehrenbacher et al.
CANCER RESEARCH (2018)
Treatment of advanced HER2-positive breast cancer: 2018 and beyond
Noam Ponde et al.
CANCER TREATMENT REVIEWS (2018)
Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
Vaheh Oganesyan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
Valeriy Domenyuk et al.
NATURE COMMUNICATIONS (2018)
Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2
Tary Traore et al.
CANCER RESEARCH (2018)
Safety, pharmacokinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.
Jifang Gong et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
Jiayu Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
Erika Paige Hamilton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer
Binghe Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
Hiroji Iwata et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors
Toshihiko Doi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H. Staudacher et al.
BRITISH JOURNAL OF CANCER (2017)
Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate
Alex Yurkovetskiy et al.
CANCER RESEARCH (2017)
SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer
P. G. Aftimos et al.
CANCER RESEARCH (2017)
Antibody-drug conjugates-an emerging class of cancer treatment
Nikolaos Diamantis et al.
BRITISH JOURNAL OF CANCER (2016)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer
D. A. Bergstrom et al.
CANCER RESEARCH (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity
Xuejing Yao et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
HER2 expression status in diverse cancers: review of results from 37,992 patients
Min Yan et al.
CANCER AND METASTASIS REVIEWS (2015)
Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers
Robin C. Humphreys et al.
CANCER RESEARCH (2015)
A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors
Donald A. Bergstrom et al.
CANCER RESEARCH (2015)
Trastuzumab-dolaflexin, a highly potent Fleximer-based antibody-drug conjugate, demonstrates a favorable therapeutic index in exploratory toxicology studies in multiple species
Natalya Bodyak et al.
CANCER RESEARCH (2015)
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
Miranda M. C. van der Lee et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985
Ronald C. Elgersma et al.
MOLECULAR PHARMACEUTICS (2015)
Tissue-based map of the human proteome
Mathias Uhlen et al.
SCIENCE (2015)
A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas Impact of 2007 American Society of Clinical Oncology/College of American Pathologists Criteria
Kurt A. Schalper et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
Wim Dokter et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab containing regimens for early breast cancer
Lorenzo Moja et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
Topoisomerase I inhibitors: camptothecins and beyond
Yves Pommier
NATURE REVIEWS CANCER (2006)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Share Paper
